Moody's Investors Service Inc said itmay upgrade the ratings on Upjohn Co's 400 mln dlrs of debt.    The agency said it will study the effect new products mayhave on Upjohn's earnings potential. Moody's will also assessthe effects that growth and a broader diversification ofpharmaceutical cash flow will have on operating performance.    Moody's noted that pharmaceuticals and other health-caremarkets are characterized by a greater stability of cash flow.    Upjohn currently carries Aa-3 senior unsecured long-termdebt and industrial revenue bonds. The company's Prime-1commercial paper is not under review. Reuter&#3;